Growth Metrics

Rockwell Medical (RMTI) EBIT Margin (2016 - 2026)

Rockwell Medical filings provide 16 years of EBIT Margin readings, the most recent being 2.17% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 7.0% to 2.17% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.77%, a 737.0% decrease, with the full-year FY2025 number at 6.77%, down 737.0% from a year prior.
  • EBIT Margin hit 2.17% in Q4 2025 for Rockwell Medical, up from 9.95% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 6.84% in Q3 2024 to a low of 54.52% in Q4 2021.
  • Median EBIT Margin over the past 5 years was 9.17% (2025), compared with a mean of 17.58%.
  • Biggest five-year swings in EBIT Margin: soared 4434bps in 2022 and later plummeted -1678bps in 2025.
  • Rockwell Medical's EBIT Margin stood at 54.52% in 2021, then skyrocketed by 81bps to 10.18% in 2022, then skyrocketed by 76bps to 2.48% in 2023, then rose by 15bps to 2.1% in 2024, then dropped by -3bps to 2.17% in 2025.
  • The last three reported values for EBIT Margin were 2.17% (Q4 2025), 9.95% (Q3 2025), and 8.39% (Q2 2025) per Business Quant data.